What is miR Scientific?
miR Scientific operates at the intersection of biotechnology and precision healthcare, specializing in the development of sophisticated diagnostic tools for urological cancers. The company's flagship innovation, the miR Sentinel Prostate Cancer Test, represents a paradigm shift in oncology, utilizing a non-invasive urine-based methodology to detect and classify disease states with high clinical accuracy. By providing actionable health intelligence to both clinicians and patients, miR Scientific effectively bridges the gap between complex molecular data and clinical decision-making. This platform is designed to replace or augment traditional, more invasive diagnostic procedures, thereby improving patient outcomes and optimizing healthcare resource allocation on a global scale.
How much funding has miR Scientific raised?
miR Scientific has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in miR Scientific
PPP
Public-Private Partnership
What's next for miR Scientific?
With the successful closure of this late-stage funding, miR Scientific is poised to scale its operational infrastructure and expand its market footprint. The strategic deployment of this capital will likely focus on broadening the clinical validation of the miR Sentinel platform and enhancing its integration into standard urological care pathways. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward securing broader regulatory approvals and establishing strategic partnerships with major healthcare providers. This growth phase is critical for establishing the company as a dominant player in the precision oncology sector, ultimately aiming to standardize its diagnostic solutions as the primary tool for early-stage cancer detection and ongoing disease management.
See full miR Scientific company page
